DE602005023592D1 - Endothelvorläuferzellen und verfahren zur verwendung davon - Google Patents

Endothelvorläuferzellen und verfahren zur verwendung davon

Info

Publication number
DE602005023592D1
DE602005023592D1 DE602005023592T DE602005023592T DE602005023592D1 DE 602005023592 D1 DE602005023592 D1 DE 602005023592D1 DE 602005023592 T DE602005023592 T DE 602005023592T DE 602005023592 T DE602005023592 T DE 602005023592T DE 602005023592 D1 DE602005023592 D1 DE 602005023592D1
Authority
DE
Germany
Prior art keywords
precursor cells
endothelial precursor
cells
immunoreactive
endothelial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005023592T
Other languages
German (de)
English (en)
Inventor
Suchitra Sumitran-Holgersson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Absorber AB
Original Assignee
Absorber AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absorber AB filed Critical Absorber AB
Publication of DE602005023592D1 publication Critical patent/DE602005023592D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0645Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4202Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203Receptors for growth factors
    • A61K40/4208Vascular endothelial growth factor receptors [VEGFR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/069Vascular Endothelial cells
    • C12N5/0692Stem cells; Progenitor cells; Precursor cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/90Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
DE602005023592T 2004-03-09 2005-03-09 Endothelvorläuferzellen und verfahren zur verwendung davon Expired - Lifetime DE602005023592D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55159404P 2004-03-09 2004-03-09
PCT/IB2005/001072 WO2005085424A2 (en) 2004-03-09 2005-03-09 Endothelial progenitor cells and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602005023592D1 true DE602005023592D1 (de) 2010-10-28

Family

ID=34919593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005023592T Expired - Lifetime DE602005023592D1 (de) 2004-03-09 2005-03-09 Endothelvorläuferzellen und verfahren zur verwendung davon

Country Status (8)

Country Link
US (2) US20050201990A1 (https=)
EP (1) EP1737949B1 (https=)
JP (2) JP2007528222A (https=)
AT (1) ATE481477T1 (https=)
AU (1) AU2005219660B2 (https=)
CA (1) CA2559110A1 (https=)
DE (1) DE602005023592D1 (https=)
WO (1) WO2005085424A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481477T1 (de) * 2004-03-09 2010-10-15 Absorber Ab Endothelvorläuferzellen und verfahren zur verwendung davon
AU2008223817A1 (en) * 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
ES2689932T3 (es) * 2008-11-04 2018-11-16 Inregen Construcciones de armazones de células
EP2198873A1 (en) * 2008-12-18 2010-06-23 Aposcience AG Pharmaceutical preparation comprising supernatant of blood mononuclear cell culture
EP2201954A1 (en) * 2008-12-18 2010-06-30 Aposcience AG Pharmaceutical preparation
US20120233218A1 (en) * 2011-03-09 2012-09-13 Christopher Liam Ivey System and Method for Delivering Brand Reinforcement as a Component of a Human Interactive Proof
US20120295347A1 (en) * 2011-05-20 2012-11-22 Steven Kessler Methods and Compositions for Producing Endothelial Progenitor Cells from Pluripotent Stem Cells
WO2014197421A1 (en) 2013-06-05 2014-12-11 Biotime, Inc. Compositions and methods for induced tissue regeneration in mammalian species
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
CN106699885B (zh) * 2015-11-18 2020-03-24 北京步长新药研发有限公司 一种人源抗vegfr2抗体及其应用
CA3202332A1 (en) 2015-12-07 2017-06-15 Agex Therapeutics, Inc. Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) * 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) * 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
NO155316C (no) * 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
US5130144B1 (en) * 1984-02-06 1995-08-15 Univ Johns Hopkins Human stem cells and monoclonal antibodies
US4965204A (en) * 1984-02-06 1990-10-23 The Johns Hopkins University Human stem cells and monoclonal antibodies
US4714680B1 (en) * 1984-02-06 1995-06-27 Univ Johns Hopkins Human stem cells
US5026365A (en) * 1987-04-29 1991-06-25 The University Of Massachusetts Method and apparatus for therapeutically treating immunological disorders and disease states
ATE81724T1 (de) * 1987-11-09 1992-11-15 Becton Dickinson Co Verfahren zur analyse haematopoietischer zellen in einer probe.
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) * 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5071741A (en) * 1988-04-18 1991-12-10 Cryolife, Inc. Cryoprotective agent and its use in cryopreservation of cellular matter
DE3829752A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
DE3829766A1 (de) * 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
US5084350A (en) * 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
CA2109085C (en) * 1991-04-25 2003-03-11 Keith E. Dionne Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5955291A (en) * 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
BR9306040A (pt) * 1992-03-06 1997-11-18 Statens Seruminstitut Tratamento e profilaxia de doenças provocadas por parasitos ou bactérias
US5840502A (en) * 1994-08-31 1998-11-24 Activated Cell Therapy, Inc. Methods for enriching specific cell-types by density gradient centrifugation
US6060643A (en) * 1995-08-04 2000-05-09 Emory University Mouse model with human immune system
US5942385A (en) * 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
US5843633A (en) * 1996-04-26 1998-12-01 Amcell Corporation Characterization of a human hematopoietic progenitor cell antigen
US20030125615A1 (en) * 1998-02-05 2003-07-03 Yitzhack Schwartz Homing of autologous cells to a target zone in tissue using active therapeutics or substances
US20030100107A1 (en) * 1998-05-29 2003-05-29 Thomas Jefferson University Compositions and methods for generating differentiated human cells
US20020150876A1 (en) * 2000-03-30 2002-10-17 Pippig Susanne Dagmar Selectable marker genes
GB0015923D0 (en) * 2000-06-30 2000-08-23 Astrazeneca Ab Methods
ATE481477T1 (de) * 2004-03-09 2010-10-15 Absorber Ab Endothelvorläuferzellen und verfahren zur verwendung davon

Also Published As

Publication number Publication date
AU2005219660A1 (en) 2005-09-15
EP1737949A2 (en) 2007-01-03
EP1737949B1 (en) 2010-09-15
WO2005085424A3 (en) 2006-05-18
AU2005219660B2 (en) 2009-07-16
ATE481477T1 (de) 2010-10-15
US20090148423A1 (en) 2009-06-11
WO2005085424A2 (en) 2005-09-15
JP2012210227A (ja) 2012-11-01
CA2559110A1 (en) 2005-09-15
US20050201990A1 (en) 2005-09-15
JP2007528222A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007149182A3 (en) Differentiation and enrichment of islet-like cells from human pluripotent stem cells
ATE486126T1 (de) Lebervorläuferzellen
WO2006050330A3 (en) Platelets from stem cells
DE602005023592D1 (de) Endothelvorläuferzellen und verfahren zur verwendung davon
WO2007030469A3 (en) Transplantable cell growth niche and related compositions and methods
MX339669B (es) Diferenciacion de celulas madres embrionarias humanas.
EP2164993A4 (en) METHOD OF MANUFACTURE AND USE OF MULTIPOTENTE CELL POPULATIONS, PLURIPOTENTAL CELL POPULATIONS, DIFFERENTIATED CELL POPULATIONS, AND HIV RESISTANT CELL POPULATIONS
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
WO2007115336A3 (en) A shape-based approach for scaffoldless tissue engineering
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
PL2274419T3 (pl) Sposoby wytwarzania mikromieszków włosowych i brodawek de novo i stosowanie ich w badaniach in vitro i przeszczepach in vivo
MY146352A (en) Adipose derived adult stem cells in hepatic regeneration
WO2008057443A3 (en) Bone marrow-derived mesenchymal stem cells as a source of neural progenitors
NZ591812A (en) Cell culture method to form aggregates
GB2453074A (en) Differentiation of primate pluripotent cells to hepatocyte-lineage cells
ATE480615T1 (de) Verfahren zur proliferation von stammzellen
ATE548447T1 (de) Menschlicher hepatische vorläuferzellen und verfahren zur verwendung davon
EP1687413A4 (en) Method for differentiating mesenchymal stem cell into neural cell and pharmaceutical composition containing the neural cell for neurodegenerative disease
DE602005018353D1 (de) Fermentierter Tee und Verfahren zur Herstellung von fermentiertem Tee
DE502005006003D1 (de) Verfahren zur herstellung einer epithelzellen enthaltenden zellzusammensetzung
WO2008058942A3 (en) Method of cell culture and method of treatment comprising a vepo protein variant
JP2007528222A5 (https=)
ATE544849T1 (de) Aktivierte dendritische zellen, therapieverfahren unter verwendung der dendritischen zellen sowie verfahren zur kultivierung von gamma-delta-t- zellen
WO2006032054A3 (en) Differentiation of human mesenchymal stem cells to cardiac progenitor cells that promote cardiac repair
ATE458808T1 (de) Verfahren zur herstellung einer voll entwickelten natürlichen killerzelle